Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Cancer / Oncology News

Early Trial Of New Multi-Kinase Inhibitor Shows Impressive Activity In Medullary Thyroid Cancer

Main Category: Cancer / Oncology
Also Included In: Endocrinology
Article Date: 23 Oct 2008 - 3:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

Preliminary trials of a new multi-kinase inhibitor have indicated it has impressive tumour shrinkage activity in patients with a difficult to treat type of thyroid cancer. The results have put the drug's development on a fast track, prompting the accelerated initiation of a large phase III trial.

The compound, XL184, targets cell growth and migration, as well as blood vessel growth (angiogenesis), through inhibition of MET kinase, VEGFR and RET kinase.

In a study presented today (Thursday 23 October) at the 20th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Geneva, 84 patients with a variety of advanced tumours that were not amenable to standard therapy were administered XL184 for either the first five days of a 14-day cycle or daily throughout the cycle. The group included 36 patients with advanced medullary thyroid cancer, for which no treatment is known to work. Response to the drug was assessed at 28 days and subsequently every eight weeks.

The impact on tumour shrinkage was particularly notable in the medullary thyroid cancer patients, where the overall disease control rate - the percentage of patients with either a partial response to the drug or prolonged stable disease for more than three months - was 84% in the 25 patients who have been followed for at least three months, said the study's presenter, Professor Steven Sherman, chair of the Department of Endocrine Neoplasia and Hormonal Disorders at M.D. Anderson Cancer Center in Houston (Texas, USA).

"Partial response, where tumours shrink by at least 30%, was achieved in 55% of the 22 patients with measurable disease who have been followed for at least three months. Most of the others experienced prolonged stable disease beyond three months, and for most of these patients there was actually tumour shrinkage. That is an impressive result for an early trial in this type of cancer," Professor Sherman said.

Three of the medullary thyroid cancer patients had unmeasurable disease. Tumour biomarkers such as plasma calcitonin and CEA [2] dropped significantly after therapy in most of the patients.

Of the 84 patients, including patients with diverse cancers, disease stabilisation for at least three months was seen in 28 cases. In sixteen of those cases, the disease was stable for six months or more, the study found. The most common adverse effects of the drug included diarrhoea (24%), nausea (18%) and fatigue (15%).

In a preclinical study presented on Friday at the conference, XL184 showed encouraging results in boosting sensitivity to erlotinib and gefitinib in drug-resistant lung cancer. Gefitinib and erlotinib belong to a class of targeted drugs that zero in on the epidermal growth factor receptor (EGFR) gene, which is mutated in many non-small cell lung cancers. MET kinase, which is inhibited by XL184, is implicated in the resistance to EGFR kinase inhibitors.

In the study, mice were grafted with human EGFR mutant and MET amplified non-small cell lung cancer tumours that were made resistant to gefitinib.

"Neither agent was effective alone, but tumour regression occurred in all animals when they were treated with a combination of erlotinib and XL184," said the mouse study's leader, Professor Pasi Janne, an assistant professor of medicine at Harvard University Medical School in Boston (Massachusetts, USA).

A clinical trial has now been initiated, testing XL184 with or without erlotinib in non-small cell lung cancer patients who have developed resistance to erlotinib. The phase III trial of XL184 in medullary thyroid cancer patients involves using the drug alone. XL184 is also being studied in glioblastoma.

Abstract nos

- 379, poster session in the poster area, 12.00-15.00 hrs CEST, Thursday 23 October.
- 552, poster session in the poster area, 12.00-15.00 hrs CEST, Friday 24 October.

[1] EORTC [European Organisation for Research and Treatment of Cancer, NCI [National Cancer Institute], AACR [American Association for Cancer Research].

[2] CEA stands for carcinoembryonic antigen.

EORTC-NCI-AACR symposium

Source
Emma Mason
EORTC media consultant
EORTC


Personalized Homepage Weekly Newsletters Daily News Alerts
Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Please fill in our survey

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Cellphones Cause Brain Tumors, Says New Report By International EMF Collaborative
26 Aug 2009
A new report, "Cellphones and Brain Tumors: 15 Reasons for Concern, Science, Spin and the Truth Behind Interphone," was released today by a collaborative of international EMF activists...


Stages of Breast Cancer image Stages of Breast Cancer

Breast cancer stages tell us the characteristics of the cancer and if it has spread beyond the breast tissue. Doctors can use this information to guide treatment decisions. Learn how staging is vital in determining next steps...

Living with Breast Cancer image Living with Breast Cancer

There are many options for treating breast cancer, including surgery, hormonal treatments, radiation and chemotherapy. All of these treatments have potential physical and emotional side effects. Discover how two women went through treatment and what they did to cope...

View more videos...